Key members of Emiliem’s management Team
Dale E. Johnson, Pharm.D., Ph.D. DABT– President , Director
Dale Johnson has over 30 years of experience in biopharmaceutical research and development activities and has participated in the research and development of over 100 compounds of which 15 have become marketed medicinal products in the U.S., Europe, and Japan. Prior to Emiliem, he served as VP, Drug Assessment & Development and VP Preclinical Development at Chiron Corporation, VP Preclinical & Predictive Development at Eos Biotechnology, Sr. Director Toxicology Research & Preclinical Safety at the Medical Research Division of American Cyanamid, Scientific Director Experimental Toxicology Division at International Research and Development Corp. (a preclinical CRO), and Sr. Research Toxicologist at Hoechst-Roussel Pharmaceuticals Inc. He was Founder & President of ddplatform LLC, a consulting firm in computational toxicology and a technology incubator. He received his Ph.D. degree in Toxicology from the University of Michigan where he was an AFPE Fellow. Prior to his Ph.D. work, he received B.S. and Pharm.D. degrees from the University of Michigan College of Pharmacy and completed a residency at UM Medical Center receiving the Squibb National Resident of the Year Award for his work on adverse drug reactions. He is a Diplomate of the American Board of Toxicology, serves as a member of industry as well as government advisory boards, and is Editor-in-Chief of the Journal of Drug Metabolism & Toxicology. Dr. Johnson was a member of the original Green Ribbon Science Panel for the State of California green chemistry initiatives. He is an Adjunct Professor at the University of California, Berkeley, Department of Nutritional Science and Toxicology, and an Adjunct Professor at the University of Michigan, Department of Environmental Health Sciences, School of Public Health.
Edwin P. Ching, J.D., Ph.D. – Vice President, Intellectual Property; Director
Edwin Ching has more than 20 years of legal experience, including Patent Counsel for Gangagen Inc. and VP, Intellectual Property at Eos Biotechnology. He has extensive experience in patent filings and prosecution in jurisdictions throughout the world. He received an A.B. in Biophysics from the University of California, Berkeley, a Ph.D. in Biochemistry and Neurobiology from California Institute of Technology, and a J.D. from Columbia University Law School. He completed post-doctoral research at Rockefeller University in Cell and Molecular Biology. He has been involved in various fundamental biotechnologies such as early genome wide “omics” platforms and large scale gene sequence analyses. Activities were primarily in the context of therapeutic drug discovery programs, both domestic and overseas. He was a Principal at ddplatform LLC and developed intellectual property that led to the formation of Emiliem.
James E. Burden, J.D. – Secretary, Director
Jim Burden has 40 years of experience in corporate finance, law practice, and business operations. After he ceased practicing law, he co-founded, financed, and operated a number of companies in the U.S. and United Kingdom. He was a co-founding director of KineMed, Inc., a company holding assay technology licensed from the University of California, Berkeley, and was Chief Operations Officer during its initial four years when the company grew from a start-up to over 50 employees. He rejoined the board of directors of KineMed, Inc in 2012 and served until November, 2013. He continues to serve as Secretary and Counsel of the company. Mr. Burden is President and majority owner of Dorset Capital, LLC, a company that facilitates the formation and financing of companies both in the U.S. and in the U.K. In 2001, he was a founding director of EuroGen Pharmaceuticals Ltd., a U.K. company formed to seek European regulatory approvals of a NASDAQ-listed company’s drug portfolio, and was a founding director of Gloucestershire Innovation Centre. Mr. Burden also serves as Director, Secretary, and C.F.O. of Elara Bioscience LLC, a company owned fifty percent by Emiliem, Inc. He received a B.S. degree from the School of Business Administration, University of California, Berkeley (Haas School of Business), a J.D. degree from the University of California, Hastings College of Law, and did post-J.D. studies at the Graduate School of Law, University of Southern California. He is a Fellow of the Institute of Directors, London, and is an active member of the California State Bar.
Sean Ekins, Ph.D., D.Sc. – Member of Scientific Advisory Board
Dr. Elkins has expertise in the areas of computational drug discovery, systems biology applied to pathway and biomarker discovery, and in vitro and computational ADME/Tox. Dr. Elkins graduated from the University of Aberdeen where he received his M.Sc., Ph.D., and D.Sc. He was a postdoctoral fellow at Lilly Research Laboratories. He has worked as a senior scientist at Pfizer, Senior Computational Chemist at Lilly Research Laboratories, Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals, Inc., Vice President of Computational Biology at GeneGo, and currently is Collaborations Director, Collaborative Drug Discovery, Inc. Sean is Adjunct Associate Professor, School of Pharmacy, Department of Pharmaceutical Sciences, University of Maryland and Adjunct Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey. Dr. Ekins has authored or co-authored over 170 peer reviewed papers and book chapters as well as edited four books on computational applications in pharmaceutical research and development and computational toxicology.
Henry C. Settle, Jr., M.B.A., C.P.A. (inactive) – Member of Business Advisory Board
Hank Settle has been a principal and a financial consultant with life sciences and technology companies since 1992. At Ernst & Young, he served as a partner in the firm’s life sciences practice in Palo Alto where he led teams serving approximately 40 emerging biotechnology and medical device companies. He began his career in E&Y’s San Diego office in 1974 and was promoted to Partner in the Tokyo office where he served as technical advisor to multi-national companies and was a member of the firm’s international mergers and acquisitions network. Subsequent to E&Y, he was Chief Financial Officer of SuperGen, Inc., a public company. He also served as a financial consultant for Affymetrix, Theravance, Inc. and E-Convergent assisting with IPOs and the design and implementation of internal business systems. Most recently, he was Chief Financial Officer of KineMed, Inc. He holds an M.B.A. in Finance from the University of California, Los Angeles, and an undergraduate degree from the University of California, Santa Barbara.